Payment overview · 2025
General Payments
$119.74
7 reported records · 6 companies
Healthcare provider profile · identity verified
Trent Eugene Gale, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LONGVIEW, TX · NPI 1972596096
Verified facts
What the public records show
CMS Open Payments records show Trent Eugene Gale, FNP received $119.74 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.99 | 26.7% | 2 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $22.75 | 19.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.48 | 17.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.49 | 14.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.27 | 14.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $8.76 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.74 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $8.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 544 | 149 |
| Prednisone | Prednisone | 475 | 262 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 119 |
| Potassium Chloride | Potassium Chloride | 457 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 453 | 124 |
| Furosemide | Furosemide | 438 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 120 |
| Gabapentin | Gabapentin | 430 | 124 |
| Lisinopril | Lisinopril | 406 | 119 |
| Azithromycin | Azithromycin | 371 | 206 |
| Losartan Potassium | Losartan Potassium | 333 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 324 | 97 |
| Carvedilol | Carvedilol | 314 | 89 |
| Clonazepam | Clonazepam | 282 | 56 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 267 | 76 |
| Metformin Hcl | Metformin Hcl | 264 | 80 |
| Omeprazole | Omeprazole | 256 | 73 |
| Glimepiride | Glimepiride | 254 | 62 |
| Tramadol Hcl | Tramadol Hcl | 242 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 66 |
| Trazodone Hcl | Trazodone Hcl | 224 | 58 |
| Cefdinir | Cefdinir | 211 | 134 |
| Diclofenac Sodium | Diclofenac Sodium | 202 | 67 |
| Montelukast Sodium | Montelukast Sodium | 195 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 50 |
| Baclofen | Baclofen | 184 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 53 |
| Buspirone Hcl | Buspirone Hcl | 174 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 55 |
| Memantine Hcl | Memantine Hcl | 153 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 33 |
| Clonidine Hcl | Clonidine Hcl | 135 | 43 |
| Sertraline Hcl | Sertraline Hcl | 133 | 39 |
| Eliquis | Apixaban | 132 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 49 |
| Meloxicam | Meloxicam | 122 | 42 |
| Simvastatin | Simvastatin | 116 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 110 | 83 |
| Allopurinol | Allopurinol | 106 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 29 |
| Alprazolam | Alprazolam | 94 | 18 |
| Donepezil Hcl | Donepezil Hcl | 94 | 24 |
| Fluconazole | Fluconazole | 94 | 55 |
| Propranolol Hcl | Propranolol Hcl | 94 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 26 |
| Spironolactone | Spironolactone | 89 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 22 |
| Clindamycin Hcl | Clindamycin Hcl | 81 | 68 |
| Sucralfate | Sucralfate | 81 | 31 |
| Atenolol | Atenolol | 80 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 76 | 52 |
| Methocarbamol | Methocarbamol | 76 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 23 |
| Divalproex Sodium | Divalproex Sodium | 64 | suppressed |
| Ondansetron Odt | Ondansetron | 64 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 23 |
| Valacyclovir | Valacyclovir Hcl | 62 | 32 |
| Topiramate | Topiramate | 61 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Ozempic | Semaglutide | 57 | 13 |
| Celecoxib | Celecoxib | 56 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 35 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Pregabalin | Pregabalin | 55 | 22 |
| Metolazone | Metolazone | 54 | 17 |
| Olanzapine | Olanzapine | 54 | suppressed |
| Amoxicillin | Amoxicillin | 53 | 28 |
| Cephalexin | Cephalexin | 51 | 41 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 16 |
| Famotidine | Famotidine | 48 | 17 |
| Linzess | Linaclotide | 48 | 13 |
| Methylprednisolone | Methylprednisolone | 46 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 15 |
| Lorazepam | Lorazepam | 44 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 21 |
| Warfarin Sodium | Warfarin Sodium | 41 | 12 |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 39 | 25 |
| Glipizide | Glipizide | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 35 |
| Temazepam | Temazepam | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 16 |
| Bupropion Xl | Bupropion Hcl | 36 | 17 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 19 |
| Levofloxacin | Levofloxacin | 35 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 13 |
| Risperidone | Risperidone | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 11 |
| Colchicine | Colchicine | 29 | 13 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Mupirocin | Mupirocin | 26 | 19 |
| Nitroglycerin | Nitroglycerin | 26 | 12 |
| Nystatin | Nystatin | 26 | 21 |
| Ramipril | Ramipril | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 12 |
| Telmisartan | Telmisartan | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Budesonide Er | Budesonide | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.74 · 7 records | ABBVIE INC. | Auvelity, Cologuard Collection Kit, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, QULIPTA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error